- About Pancreatic Cancer
- Get Support
Caregivers
- Get Involved
- Events
- More
2015-10-01
2017-05-27
2017-10-26
8
NCT02580422
Indiana University
Indiana University
OBSERVATIONAL
Pilot Project for Cardiopulmonary and Functional Evaluation in Patients With Pancreatic Cancer Associated Cachexia
Cachexia is a systemic catabolic syndrome with apparent effect on skeletal muscles, tolerance to chemotherapy, early toxicity and quality of life; however, its effect on cardiopulmonary function is not well understood. Preclinical studies demonstrated diaphragmatic muscle wasting(29) and left ventricular wasting and fibrosis associated with mouse cachexia models.(40) Many patients, who experience cancer cachexia, describe a generalized debility and a sense of breathlessness(41) despite adequate oxygenation in the peripheral blood as measured by pulse oximetry. Whether this is related to deconditioning associated with chemotherapy or related to direct effect on cardiac and diaphragmatic muscles remains unknown. In this pilot study, the investigators propose to perform a preliminary evaluation of the cardiopulmonary function in patients with pancreatic cancer, who are likely to develop cachexia, to assess for the feasibility of performing a larger prospective study to understand the impact of cancer cachexia on cardiopulmonary function. This pilot study will provide the foundation to potentially identify cachexia in early stages (pre-cachexia) to develop pharmacological or exercise based interventions to prevent or delay its progression. Based on clinical experience and published literature, it is expected that 60-70% of patients will have >10% weight loss during the course of this disease. More commonly, this is associated with clinical or radiographic disease progression, but certainly it can happen throughout the course of the disease even without disease progression.
Primary Objective: To assess the feasibility of performing a prospective cardiopulmonary and physical function assessment in patients with advanced pancreatic ductal adenocarcinoma (PDAC) who are expected to develop cachexia. Secondary Objectives: 1. To measure the changes in maximal expiratory pressure (MEP) and maximal inspiratory pressure (MIP) in patients with progressive PDAC and/or cancer associated cachexia 2. To measure changes in strain echocardiography in patients with progressive PDAC and/or cancer associated cachexia 3. To assess functional changes in patients with progressive PDAC and/or cancer associated cachexia 4. To assess body composition changes associated with cachexia or disease progression 5. To measure the levels of cytokines from peripheral blood in patients with cachexia Procedures: All study procedures will be done at two time points (T1=baseline or study entry, T2=at disease progression or development of cachexia). Patients will undergo echocardiography with strain evaluation at Indiana University Health Echocardiography Laboratory and pulmonary function tests as per institutional guidelines at IUH PFT laboratory at University Hospital. Patients will also have 20mL (2 red top tubes) of blood drawn for the studies outlined in Section 7.5. Standard of care labs will be taken from the patient's medical records. Patients also will be evaluated using three standardized functional assessment tools commonly utilized in physical rehabilitation: 1) 5 Times Sit-to-Stand Test; 2) 6 Minute Walk Test; and 3) grip dynamometry. Standard of care CT scan obtained at the time of tumor assessment will enable the investigators to assess body muscle mass as described in Section 7.4. In addition, the investigators will administer three standardized survey tools to assess quality of life and prior level of function: 1) The Short Form 36 (SF-36); 2) Lower Extremity Functional Scale (LEFS); and 3) Scored Patient-Generated Subjective Global Assessment (PG-SGA). Sample Size: Due to the risk of clinical deterioration or drop out of the study and inability to undergo T2 evaluation, the investigators will plan on enrolling 133% of desired number of subjects, accounting for 33% missing T2 data. This is likely a high number; however, this will enable data collection from 12-15 patients at both time points and all proposed tests.
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
| Study Registration Dates | Results Reporting Dates | Study Record Updates |
|---|---|---|
2015-10-06 | N/A | 2018-02-21 |
2015-10-19 | N/A | 2018-02-23 |
2015-10-20 | N/A | 2018-02 |
This section provides details of the study plan, including how the study is designed and what the study is measuring.
Primary Purpose:
N/A
Allocation:
N/A
Interventional Model:
N/A
Masking:
N/A
Arms and Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|
| Primary Outcome Measures | Measure Description | Time Frame |
|---|---|---|
| The number of patients who have changes in echocardiography, pulmonary function or one or more part of their functional evaluation tests | Changes are significant if they are > 15% from baseline. Development of cachexia is defined by ≥ 10% of weight loss from baseline. | Baseline to disease progression or development of cachexia (approximately 6 months) |
| Secondary Outcome Measures | Measure Description | Time Frame |
|---|---|---|
| Change in pulmonary function | Measured by comparing scores (maximal expiratory pressure [MEP] and maximal inspiratory pressure [MIP]) from forced spirometry with folow volume loop test. | Baseline to disease progression or development of cachexia (approximately 6 months) |
| Change in strain echocardiogram | Measured by comparing strain echocardiograms | Baseline to disease progression or development of cachexia (approximately 6 months) |
| Change in self-reported quality of life | Measured by comparing Short Form-36 questionnaire scores | Baseline to disease progression or development of cachexia (approximately 6 months) |
| Change in self-reported function via LEFS questionnaire | Measured by comparing Lower Extremity Functional Scale (LEFS) questionnaire scores | Baseline to disease progression or development of cachexia (approximately 6 months) |
| Change in self-reported function via PG-SGA questionnaire | Measured by comparing Patient-Generated Subjective Global Assessment (PG-SGA) questionnaire scores | Baseline to disease progression or development of cachexia (approximately 6 months) |
| Change in functional evaluation test | Measured by comparing grip dynamometry, 6-minute walk test, 5-minute sit-to-stand test scores | Baseline to disease progression or development of cachexia (approximately 6 months) |
| Change in body composition via CT scan | Measured by comparing CT scans that are analyzed using Sliceomatic (Tomovision) technology | Baseline to disease progression or development of cachexia (approximately 6 months) |
| Change in levels of cytokines | Measured through blood samples collected at each time point which are evaluated for cytokine levels using enzyme-linked immunosorbent assay (ELISA). | Baseline to disease progression or development of cachexia (approximately 6 months) |
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.
Ages Eligible for Study:
ALL
Sexes Eligible for Study:
Accepts Healthy Volunteers:
This is where you will find people and organizations involved with this study.
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
